Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 02 Nov 2020 Status changed from active, no longer recruiting to completed.
- 26 Aug 2020 Planned End Date changed from 17 Oct 2020 to 28 Oct 2020.
- 27 Jul 2020 Planned End Date changed from 30 Oct 2020 to 17 Oct 2020.